摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

α-Peltatin 5-O-β-D-glucoside | 11024-58-1

中文名称
——
中文别名
——
英文名称
α-Peltatin 5-O-β-D-glucoside
英文别名
α-peltatin β-D-glucoside;(5aR)-10-β-D-glucopyranosyloxy-5t-(4-hydroxy-3,5-dimethoxy-phenyl)-(5ar,8at)-5,8,8a,9-tetrahydro-5aH-furo[3',4';6,7]naphtho[2,3-d][1,3]dioxol-6-one;(5aR)-10-β-D-Glucopyranosyloxy-5t-(4-hydroxy-3,5-dimethoxy-phenyl)-(5ar,8at)-5,8,8a,9-tetrahydro-5aH-furo[3',4';6,7]naphtho[2,3-d][1,3]dioxol-6-on;(5aR,8aR,9R)-9-(4-hydroxy-3,5-dimethoxyphenyl)-4-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-5a,6,8a,9-tetrahydro-5H-[2]benzofuro[6,5-f][1,3]benzodioxol-8-one
α-Peltatin 5-O-β-D-glucoside化学式
CAS
11024-58-1
化学式
C27H30O13
mdl
——
分子量
562.527
InChiKey
HUCNZRPYZDCCEF-NSLKGFGYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    0.8
  • 重原子数:
    40
  • 可旋转键数:
    6
  • 环数:
    6.0
  • sp3杂化的碳原子比例:
    0.52
  • 拓扑面积:
    183
  • 氢给体数:
    5
  • 氢受体数:
    13

反应信息

  • 作为反应物:
    参考文献:
    名称:
    Lignanglucoside AUS鬼臼盾叶大号。7. Mitteilungübermitosehemmende Naturstoffe †
    摘要:
    从美洲鬼臼的根茎。可以分离并鉴定具有抗有丝分裂活性的四种木脂素葡糖苷:鬼臼毒素-β-D-葡糖苷(IX),β-类维生素A-β-D-葡糖苷(XI),4'-去甲基鬼臼毒素-β-D-葡糖苷(X)和α-peltatin-β-u-葡萄糖苷(XII)。根据以下事实推论β-类维生素A-β-D-葡萄糖苷的组成:用乳胶酶解产生D-葡萄糖和已知的β-类胡萝卜素。α-Peltatin-β-D-葡萄糖苷是鬼臼类中第一个以结晶形式分离的天然葡萄糖苷,经乳化酶水解后分解为D-葡萄糖和α-peltatin。可以通过甲基化为鬼臼毒素-β-D-葡萄糖苷和β-peltatin-β-D-的甲基化来确定4'-去甲基鬼臼毒素-β-D-葡萄糖苷和α-peletatin-β-D-葡萄糖苷中糖成分的位置。糖苷。
    DOI:
    10.1002/hlca.19570400525
点击查看最新优质反应信息

文献信息

  • Antitumor agents. 100. Inhibition of human DNA topoisomerase II by cytotoxic ether and ester derivatives of podophyllotoxin and .alpha.-peltatin
    作者:Lee S. Thurston、Yasuhiro Imakura、Mitsumasa Haruna、De Hua Li、Zong Chao Liu、Su Ying Liu、Yung Chi Cheng、Kuo Hsiung Lee
    DOI:10.1021/jm00123a016
    日期:1989.3
    A principal mechanism of action of the clinical antitumor drugs etoposide (1) and teniposide (2) is the inhibition of catalytic activity of type II DNA topoisomerase and concurrent enzyme-mediated production of lethal DNA strand breaks. Substitution of the glycosidic moiety of 1 or 2 by ester and ethers, as well as the esterification and etherification of alpha-peltatin (4) including its glucosidic ethylidene and thenylidene cyclic acetals (25 and 26), has afforded compounds of much less activity than that of 1. The in vitro cytotoxicity (KB) appears to have no correlation with the inhibitory activity of the human DNA topoisomerase II.
  • THURSTON, LEE S.;IMAKURA, YASUHIRO;HARUNA, MITSUMASA;LI, DE-HUA;LIU, ZONG+, J. MED. CHEM., 32,(1989) N, C. 604-608
    作者:THURSTON, LEE S.、IMAKURA, YASUHIRO、HARUNA, MITSUMASA、LI, DE-HUA、LIU, ZONG+
    DOI:——
    日期:——
查看更多

同类化合物

鹅掌楸碱 罗汉松树脂酚-4'-O-β-龙胆二糖苷 络石苷元-4'-O-BETA-龙胆二糖苷 络石苷 牛蒡苷 牛蒡子苷元-4'-O-Β-龙胆二糖苷 柑属苷B 松脂醇二葡萄糖苷 松脂醇-4-O-beta-D-吡喃葡萄糖苷 松脂醇 beta-D-吡喃葡萄糖苷 木須皮苷 异落叶松脂素9'-BETA-D-吡喃木糖苷 异落叶松脂素-9'-O-beta-D-吡喃葡萄糖苷 开环异落叶松脂素BETA-D-葡糖苷 地菲林葡萄糖苷 去甲络石苷 南烛木糖甙 刺五加苷D 刺五加甙E 刺五加甙 E 刺五加提取物 丁香树脂醇双葡萄糖苷 b-D-吡喃葡萄糖苷,4-[(1R,2R)-1,3-二羟基-2-[4-[(1E)-3-羟基-1-丙烯-1-基]-2-甲氧基苯氧基]丙基]-2-甲氧苯基 Ssioriside; (2S,3S)-4-羟基-2,3-双[(4-羟基-3,5-二甲氧基苯基)甲基]丁基 beta-D-吡喃木糖苷 8-羟基松脂醇二葡萄糖苷 8-O-(α-阿拉伯呋喃糖)-β-àpeltatin 4-[(5S,5aR,8aS)-10-羟基-6-羰基-5,5a,6,8,8a,9-六氢呋喃并[3',4':6,7]萘并[2,3-d][1,3]二噁唑-5-基]-2,6-二甲氧苯基α-L-呋喃阿拉伯糖苷 4-(1,3-苯并二氧戊环-5-基)-9-[(2S,3R,4S,5R)-3,4-二甲氧基-5-[(2S,3R,4S,5S,6R)-3,4,5-三羟基-6-(羟基甲基)四氢吡喃-2-基]氧基四氢吡喃-2-基]氧基-6,7-二甲氧基-1H-苯并[f][2]苯并呋喃-3-酮 4-(1,3-苯并二氧戊环-5-基)-6,7-二甲氧基-9-[(2S,3R,4S,5S,6R)-3,4,5-三羟基-6-(羟基甲基)四氢吡喃-2-基]氧基-1H-苯并[f][2]苯并呋喃-3-酮 3-[2,3-二氢-6-羟基-2-(1-羟基-1-甲基乙基)苯并呋喃-5-基]-8-(beta-D-吡喃葡萄糖基)-2,3-二氢-5,7-二羟基-4H-1-苯并吡喃-4-酮 2,3-双(3-甲氧基-4-羟基苄基)丁烷-1,4-二醇 1,4-二葡萄糖甙 (3S,4R)-4-(苯并[1,3]二氧杂环戊烯-5-基甲基)-3-[(S)-[(2R,3R,4S,5R,6R)-3,4,5-三羟基-6-(羟基甲基)四氢吡喃-2-基]氧基-(3,4,5-三甲氧基苯基)甲基]四氢呋喃-2-酮 (3R,4S)-3-[[4-(beta-D-吡喃葡萄糖基氧基)-3-甲氧基苯基]甲基]-4,5-二氢-4-[(4-羟基-3-甲氧基苯基)甲基]呋喃-2(3H)-酮 (3-苯甲酰氧基-2-羟基-4,5-二苯基-四氢-[2]呋喃基)-苯基酮 (2S)-5,7-二羟基-2-[4-[2,4,6-三羟基-3-[(E)-3-(4-羟基苯基)丙-2-烯酰基]-5-[(2S,3R,4R,5S,6R)-3,4,5-三羟基-6-(羟基甲基)四氢吡喃-2-基]苯氧基]苯基]色满-4-酮 (-)-异落叶松脂素-9'-O-BETA-D-吡喃葡萄糖苷 (+)-南烛木树脂酚9'-O-葡萄糖甙 4-O-[6-O-(5-O-syringoyl-β-D-apiofuranosyl)-β-D-glucopyranosyl]-(+)-(7S,7'R,8R,8'R)-4'-hydroxy-3,3',5,5'-tetramethoxy-7,9':7',9-diepoxylignane (+)-1-hydroxypinoresinol 4'-O-β-glucopyranoside hexaacetate (+)-1-hydroxypinoresinol 4''-O-β-glucopyranoside 2''',3''',4''',4',6'''-O-pentaacetate (+)-1-hydroxypinoresinol 4''-O-β-glucopyranoside hexaacetate Acetic acid (3R,4S,5R)-2-(9-benzo[1,3]dioxol-5-yl-8-oxo-6,8-dihydro-furo[3',4':6,7]naphtho[2,3-d][1,3]dioxol-5-yloxy)-4,5-dimethoxy-tetrahydro-pyran-3-yl ester (+)-1-hydroxypinoresinol 4'-O-β-glucopyranoside 2''',3''',4''',4'',6'''-O-pentaacetate 4'-acetoxy-6-C-(2,3,4-tri-O-acetyl-α-D-arabinopyranosyl)-8-C-(2,3,4,6-tetra-O-acetyl-β-D-glucopyranosyl)-5,7-dihydroxyflavan (2S,3R,4S,5S,6R)-2-[4-[(2R,3R)-4-hydroxy-3-[(4-hydroxy-3-methoxyphenyl)methyl]-2-(hydroxymethyl)butyl]-2-methoxyphenoxy]-6-(hydroxymethyl)oxane-3,4,5-triol Acetic acid (2S,3R,4S,5R,6R)-4,5-diacetoxy-6-acetoxymethyl-2-[(5S,5aR,8aR)-9-(4-hydroxy-3,5-dimethoxy-phenyl)-8-oxo-5,5a,6,8,8a,9-hexahydro-furo[3',4':6,7]naphtho[2,3-d][1,3]dioxol-5-ylsulfanyl]-tetrahydro-pyran-3-yl ester 2,2-difluoro-N-((5S,5aS,8aR,9R)-8-oxo-9-(3,4,5-trimethoxyphenyl)-5,5a,6,8,8a,9-hexahydrofuro[3',4':6,7]naphtho[2,3-d][1,3]dioxol-5-yl)-2-((2R,3R,4S,5S,6R)-2,3,4,5-tetrahydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)acetamide 2,2-difluoro-N-((5S,5aS,8aR,9R)-9-(4-hydroxy-3,5-dimethoxyphenyl)-8-oxo-5,5a,6,8,8a,9-hexahydrofuro[3',4':6,7]naphtho[2,3-d][1,3]dioxol-5-yl)-2-((2R,3R,4S,5R,6R)-2,3,4,5-tetrahydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)acetamide 2,2-difluoro-N-((5S,5aS,8aR,9R)-8-oxo-9-(3,4,5-trimethoxyphenyl)-5,5a,6,8,8a,9-hexahydrofuro[3',4':6,7]naphtho[2,3-d][1,3]dioxol-5-yl)-2-((2R,3R,4S,5R,6R)-2,3,4,5-tetrahydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)acetamide